Champions Oncology Inc. 2026年季度报告

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuantto Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller Large accelerated filerAccelerated filerNon-accelerated filerSmaller reporting company☑Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐NoThe number of shares of common stock of the Registrant outstanding as of March 11, 2026 was 13,886,826.DOCUMENTS INCORPORATED BY REFERENCE - None CHAMPIONS ONCOLOGY, INC.NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Note 1. Organization, Use of Estimates and Basis of Presentation Champions Oncology, Inc. (the "Company", or "we", or "our") is engaged in drug discovery and development through data-drivenresearch strategies and innovative pharmacology, biomarker and data platforms. The Company’s TumorGraft Technology Platform (the"Platform"), a comprehensive bank of unique, well characterized "Patient Derived XenoGrafts" (PDX) models, is an approach topersonalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The Company provides a technologyplatform to pharmaceutical and biotechnology companies using proprietary TumorGraft studies, which the Company believes may be The Company has four operating subsidiaries: Champions Oncology (Israel), Limited, Champions Oncology U.K. Limited, ChampionsOncology, S.R.L. (Italy), and Corellia A.I. Inc. ("Corellia"). For the three and nine months ended January 31, 2026 and 2025, there were norevenues earned by these subsidiaries. The Company’s foreign subsidiaries' functional currency is the U.S. dollar. Transaction gains and losses are recognized in earnings.The Company is subject to foreign exchange rate fluctuations in connection with the Company’s international operations. The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principlesgenerally accepted in the United States of America ("GAAP"). The Company operates in one reportable business segment. The condensedconsolidated financial statements include the accounts of the Company and its subsidiaries in which it holds a controlling financial interest.Intercompanytransactions and accounts have been eliminated.The Company's wholly owned subsidiary,Corellia,has issued These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of theSecurities and Exchange Commission, or the SEC. Certain information related to the Company’s organization, significant accountingpolicies and footnote disclosures normally included in financial statements prepared in accordance with GAAP has been condensed oromitted. The April 30, 2025 condensed consolidated balance sheet in the accompanying interim condensed consolidated financialstatements was derived from audited consolidated financial statements. The accounting policies followed in the preparation of theseunaudited condensed consolidated financial statements are consistent with those followed in the Company’s annual consolidated financial The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affectthe reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and Note 2. Significant Accounting Policies The significant accounting policies used in the preparation of these condensed consolidated financial statements are disclosed in our2025 Annual Report and there have been no changes to the Company's significant accounting policies during the nine months ended Liquidity The Company's liquidity needs have typically arisen from the funding of its research and development programs and the launch of newproducts and services, working capital requirements, and other strategic initiatives. Historically, the Company has met these cashrequirements through cash on hand, working capital management, and sales of products and services. In the past, the Company has alsoreceived proceeds from certain private placements and public offerings of our securities. For the nine months ended January31, 2026, theCompany had a net loss of approximately $508,000, an accumulated deficit